Abstract
e19052Background: Duvelisib (IPI-145), an oral dual inhibitor of PI3K-δ and -γ, is being evaluated as an oral therapeutic for hematologic malignancies as a monotherapy or in combination with anti-C...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have